Dow Jones
33.891,02 -34,99 (-0,10%) Nasdaq
11.887,45 -119,50 (-1,00%) Nikkei 225
27.693,65 +184,19 (+0,67%) EUR/USD
1,0730 -0,0067 (-0,62%) BTC-EUR
21.453,60 -41,69 (-0,19%) CMC Crypto 200
528,84 +3,71 (+0,71%)
QuidelOrtho Corporation (0A55.L)
| Chiusura precedente | 86,22 |
| Aperto | 90,47 |
| Denaro | 0,00 x N/D |
| Lettera | 0,00 x N/D |
| Min-Max giorno | 90,47 - 90,83 |
| Intervallo di 52 settimane | 90,47 - 90,83 |
| Volume | |
| Media Volume | N/D |
| Capitalizzazione | N/D |
| Beta (5 anni mensile) | 0,28 |
| Rapporto PE (ttm) | 0,04 |
| EPS (ttm) | 23,62 |
| Prossima data utili | 15 feb 2023 - 20 feb 2023 |
| Rendimento e dividendo (forward) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
- GlobeNewswire
QuidelOrtho to Report Second Quarter 2022 Financial Results on August 4, 2022
SAN DIEGO, July 18, 2022 (GLOBE NEWSWIRE) -- QuidelOrtho Corporation (NASDAQ: QDEL) (“QuidelOrtho”), a leading in vitro diagnostics company, today announced it will report financial results for its second quarter 2022 ended July 3, 2022, after the market close on Thursday, August 4, 2022. Following the release of the financial results, QuidelOrtho will hold a conference call beginning at 2:00 p.m. PDT / 5:00 p.m. EDT to discuss the financial results. Interested parties can access the conference
- GlobeNewswire
Quidel and Ortho Announce Expected Closing of Ortho Transaction
SAN DIEGO, May 26, 2022 (GLOBE NEWSWIRE) -- Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, and Ortho Clinical Diagnostics Holdings plc (“Ortho”), one of the world’s larger pure-play in vitro diagnostics companies, announced today that the closing of the previously announced Ortho transaction is expected to occur on May 27, 2022. On May 26, 2022, the High Court of Justice of England a
- GlobeNewswire
Ortho Clinical Diagnostics Shareholders Approve Quidel Transaction
RARITAN, N.J., May 16, 2022 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics Holdings plc (NASDAQ: OCDX) (“Ortho” or the “Company”), one of the world’s largest pure-play in vitro diagnostics (IVD) companies, today announced that based on a preliminary vote count by its proxy solicitor, Ortho shareholders have voted to approve the combination of the Company with Quidel Corporation (NASDAQ: QDEL) (“Quidel”) pursuant to the Business Combination Agreement, dated December 22, 2021, by and among the Com
